Cara Therapeutics, Inc. (CARA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 9.13 |
| Open | 9.02 |
| Bid | 8.08 x 1300 |
| Ask | 9.44 x 800 |
| Day's Range | 8.26 - 9.28 |
| 52 Week Range | 7.40 - 18.93 |
| Volume | |
| Avg. Volume | 664,040 |
| Market Cap | 460.814M |
| Beta (5Y Monthly) | 1.09 |
| PE Ratio (TTM) | 18.00 |
| EPS (TTM) | 0.48 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.00 |
- Benzinga
Cara Therapeutics' Difelikefalin Aces Mid-Stage Study In Patients With Itchy Skin Disorder
Cara Therapeutics Inc (NASDAQ: CARA) announced topline results from its Phase 2 proof-of-concept trial (KOMFORT) of difelikefalin for moderate-to-severe pruritus in patients with notalgia paresthetica, a nerve disorder characterized by chronic pruritus (itchy skin) of the upper to middle back. The primary efficacy endpoint was the change from baseline in the weekly mean of the daily 24-hour itch scale (WI-NRS) score at Week 8. Other endpoints included the ≥4-point responder analysis, itch-relate
- GlobeNewswire
Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica
– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and sustained through Week 8 – – Statistical significance achieved on the WI-NRS ≥4-point responder analysis at Week 8 (p=0.007) – – Oral difelikefalin was well tolerated with a consistent safety profile – – Conference call today at 8:30 a.m. ET – STAMFORD, Conn., June 30, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commerci
- Insider Monkey
10 Best CBD Stocks To Invest In
In this article, we discuss the 10 best CBD stocks to invest in. You can skip our detailed analysis of these stocks and the current market situation, and go directly to 5 Best CBD Stocks To Invest In. With the growing acceptance of cannabis among global consumers and their elected representatives, the CBD market has […]
